DV
Dividend Vision

IFRX — InflaRx N.V.

InflaRx N.V. (IFRX)

Total return is -86.4% over the past 8.8 years, 329.4 points behind SPY at 243.0%. Its deepest 1-year drawdown was 52.8%.

InflaRx N.V. is a clinical-stage biopharmaceutical company developing inhibitors based on C5a technology to treat autoimmune and inflammatory diseases, with its lead candidate vilobelimab in Phase 3 trials for septic organ dysfunction and other programs in earlier development stages. The company does not currently distribute dividends. InflaRx appeals to investors seeking exposure to early-stage biotech development rather than current income, with returns dependent on clinical trial progress and regulatory outcomes.

IFRX key facts

Asset type
Stock
Asset class
Equity
Inception date
11/08/2017
Last close
$2.04
Market cap
$272,491,808
Average volume
1468326.0
Beta
2.455
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.72